Analyzing Trulieve Cannabis (TRLV) & Its Rivals

Trulieve Cannabis (NYSE:TRLV) is one of 898 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare Trulieve Cannabis to similar companies based on the strength of its risk, analyst recommendations, institutional ownership, profitability, valuation, earnings and dividends.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Trulieve Cannabis and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trulieve Cannabis	1	1	1	0	2.00
Trulieve Cannabis Competitors	7776	13819	25649	1029	2.41

Trulieve Cannabis presently has a consensus price target of $15.00, indicating a potential upside of 44.27%. As a group, “Pharmaceuticals” companies have a potential upside of 31.30%. Given Trulieve Cannabis’ higher probable upside, equities research analysts clearly believe Trulieve Cannabis is more favorable than its rivals.

Profitability

This table compares Trulieve Cannabis and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Trulieve Cannabis	-41.55%	-4.24%	-1.72%
Trulieve Cannabis Competitors	-2,378.16%	-221.76%	-16.00%

Valuation and Earnings

This table compares Trulieve Cannabis and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Trulieve Cannabis	$1.18 billion	-$116.38 million	94.52
Trulieve Cannabis Competitors	$4.60 billion	$3.22 billion	554.07

Trulieve Cannabis’ rivals have higher revenue and earnings than Trulieve Cannabis. Trulieve Cannabis is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

32.4% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 3.8% of Trulieve Cannabis shares are owned by company insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Trulieve Cannabis rivals beat Trulieve Cannabis on 8 of the 12 factors compared.

About Trulieve Cannabis

Trulieve Cannabis Corp., together with its subsidiaries, operates as a medical cannabis company. The company cultivates and produces products in-house and distributes its products to Trulieve branded stores (dispensaries) in Florida, California, Massachusetts, Connecticut, Pennsylvania, and West Virginia, as well as directly to patients through home delivery. It produces approximately 550 stock keeping units, including flower, edibles, vaporizer cartridges, concentrates, topicals, capsules, tinctures, dissolvable powders, and nasal sprays. As of May 5, 2021, the company operated through 87 dispensaries in the United States. The company is headquartered in Quincy, Florida.